title: Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss.
abstract: OBJECTIVE
  To evaluate the potential body weight-lowering effects of dietary supplementation with eicosapentaenoic acid (EPA) and α-lipoic acid separately or combined in healthy overweight/obese women following a hypocaloric diet.
  
  
  METHODS
  This is a short-term double-blind placebo-controlled study with parallel design that lasted 10 weeks. Of the randomized participants, 97 women received the allocated treatment [Control, EPA (1.3 g/d), α-lipoic acid (0.3 g/d), and EPA+α-lipoic acid (1.3 g/d+0.3 g/d)], and 77 volunteers completed the study. All groups followed an energy-restricted diet of 30% less than total energy expenditure. Body weight, anthropometric measurements, body composition, resting energy expenditure, blood pressure, serum glucose, and insulin and lipid profile, as well as leptin and ghrelin levels, were assessed at baseline and after nutritional intervention.
  
  
  RESULTS
  Body weight loss was significantly higher (P<0.05) in those groups supplemented with α-lipoic acid. EPA supplementation significantly attenuated (P<0.001) the decrease in leptin levels that occurs during weight loss. Body weight loss improved lipid and glucose metabolism parameters but without significant differences between groups.
  
  
  CONCLUSIONS
  The intervention suggests that α-lipoic acid supplementation alone or in combination with EPA may help to promote body weight loss in healthy overweight/obese women following energy-restricted diets.
authors.affiliation: Department of Nutrition, Food Science and Physiology, University of Navarra, Pamplona, Spain; Centre for Nutrition Research, Faculty of Pharmacy, University of Navarra, Pamplona, Spain.
authors.forename: Ana E
authors.initials: AE
authors.lastname: Huerta
authors.forename: Santiago
authors.initials: S
authors.lastname: Navas-Carretero
authors.forename: Pedro L
authors.initials: PL
authors.lastname: Prieto-Hontoria
authors.forename: J Alfredo
authors.initials: JA
authors.lastname: Martínez
authors.forename: María J
authors.initials: MJ
authors.lastname: Moreno-Aliaga
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000975:Antioxidants / Q000008:administration & dosage*; D001823:Body Composition; D002784:Cholesterol / Q000097:blood; D019587:Dietary Supplements; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage* / Q000097:blood; D004734:Energy Metabolism; D005260:Female; D054439:Ghrelin / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D008063:Thioctic Acid / Q000008:administration & dosage* / Q000097:blood; D016896:Treatment Outcome; D015431:Weight Loss; D055815:Young Adult
chemical_list: D000975:Antioxidants; D054439:Ghrelin; D007328:Insulin; D020738:Leptin; D008063:Thioctic Acid; D002784:Cholesterol; D015118:Eicosapentaenoic Acid; D005947:Glucose